Anti-Cancer Chemotherapy for Colorectal Cancer — NCD 291 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 291 governing anti-cancer chemotherapy coverage for colorectal cancer, effective January 9, 2026. Here's what changes for billing teams.

CMS updated its colorectal cancer chemotherapy coverage policy under NCD 291 Medicare framework, clarifying how oxaliplatin, irinotecan, cetuximab, and bevacizumab are covered — both for FDA-approved indications and off-label use in NCI-sponsored clinical trials. This policy does not list specific CPT or HCPCS codes, but it directly affects how your billing team documents and submits claims for these four agents. If your practice or facility bills for any of these drugs, read this before January 9, 2026.

Quick-Reference Table

CMS Colorectal Cancer Chemotherapy Coverage Criteria and Medical Necessity Requirements 2026

The core of this coverage policy hasn't flipped upside down. CMS still covers oxaliplatin, irinotecan, cetuximab, and bevacizumab under three distinct pathways. Understanding which pathway applies to each claim determines whether you get paid — or get a claim denial.

Pathway 1: FDA-Approved Indications
When you bill for any of these four drugs under an FDA-approved indication, coverage applies under section 1861(t)(2)(B) of the Social Security Act. Medical necessity documentation needs to align with the approved labeling. This is your cleanest path to reimbursement.

Pathway 2: Off-Label Use Supported by an Authoritative Compendium
If the use is off-label but appears in one of the authoritative drug compendia listed in section 1861(t)(2)(B)(ii)(I) of the Act, the drug is still eligible for coverage. Your documentation needs to show the compendium supports that specific use. This is where billing teams often get sloppy — make sure your clinical team identifies the exact compendium reference at the time of order, not after a denial lands.

Pathway 3: Off-Label Use in NCI-Sponsored Clinical Trials
This is what the January 9, 2026 modification specifically addresses. CMS covers the off-label use of oxaliplatin, irinotecan, cetuximab, or bevacizumab when the use occurs within a specific NCI-sponsored clinical trial identified by CMS. These aren't just any trials — they have to appear on the CMS-identified trial list. The full list lives at the CMS website referenced in the policy document.

The medical necessity standard here ties directly to trial enrollment. If your patient is enrolled in one of the listed trials, coverage applies for those off-label uses studied in that trial. If the trial isn't on the CMS list, this pathway doesn't apply.

MAC-Level Determinations Still Matter
Medicare Administrative Contractors retain authority under section 1861(t)(2)(B)(ii)(II) to make coverage determinations for off-label uses that fall outside the FDA labeling and compendium pathways — but only for uses outside the identified clinical trials. Your MAC's local coverage determination history on these agents should still be on your radar. Don't assume NCD 291 overrides everything at the local level for uses that aren't trial-related.

Prior authorization requirements under this policy follow standard Medicare rules for chemotherapy administration. CMS doesn't impose a separate prior authorization layer under NCD 291 for the clinical trial pathway, but your MAC may have billing guidelines that require advance documentation. Check with your MAC before billing clinical trial claims for the first time.

Coverage Indications at a Glance

CMS Colorectal Cancer Chemotherapy Billing Guidelines and Action Items 2026

1. Verify the CMS clinical trial list before billing any off-label trial claims after January 9, 2026.
The NCI-sponsored trials covered under this policy are listed on the CMS website. If your facility is participating in an oncology trial that studies oxaliplatin, irinotecan, cetuximab, or bevacizumab in off-label settings, confirm that specific trial appears on the CMS list before the effective date. A trial being NCI-sponsored does not automatically mean it's on the CMS-identified list. These are two different things.

2. Document the coverage pathway in the medical record for every claim.
Each claim for these four drugs should make the coverage basis obvious — FDA-approved indication, compendium-supported off-label use, or CMS-identified clinical trial enrollment. Auditors and MACs look for this. Missing documentation is the most common reason anti-cancer chemotherapy billing generates a claim denial on review.

3. Update your charge capture workflows to flag off-label drug use at the point of order.
When a provider orders oxaliplatin, irinotecan, cetuximab, or bevacizumab for an off-label indication, your charge capture system should prompt for the coverage basis before the claim goes out. This is a process fix that pays for itself the first time it catches a documentation gap. Build it before January 9, 2026, not after.

4. Confirm compendium references for off-label claims are current.
The authoritative compendia listed in section 1861(t)(2)(B)(ii)(I) of the Act get updated. An off-label use that was in a prior edition may not be in the current one, or the language may have changed. Your oncology billing team should verify compendium support for every recurring off-label use at least annually — and definitely before the effective date of this modification.

5. Audit routine cost billing for clinical trial patients against NCD 310.1.
This policy explicitly preserves existing coverage for routine costs under NCD Manual section 310.1. If you're billing routine costs for patients enrolled in one of the NCI-sponsored trials covered here, those claims follow NCD 310.1 rules — not NCD 291. Make sure your billing team isn't conflating the two policies. Routine cost claims submitted under the wrong NCD are a clean path to a denial.

6. Check with your MAC on local coverage determination guidance for off-label uses outside trials.
MACs retain independent authority to cover off-label uses of these four drugs outside of identified trials. If you're billing for a medically accepted off-label use that doesn't fit the FDA or compendium pathways and isn't in a listed trial, your MAC's local coverage determination and guidance from the Secretary govern. Don't assume NCD 291 provides a blanket answer. If you're unsure how this applies to your patient mix, talk to your compliance officer before the January 9, 2026 effective date.

7. Review transmittal R588CP for claims processing instructions.
CMS published claims processing instructions under Transmittal R588CP (Medicare Claims Processing). Your billing team should review this transmittal directly — it contains the operational details that translate this NCD into actual claim submission requirements. The transmittal link appears in the policy cross-references.

CPT, HCPCS, and ICD-10 Codes for Colorectal Cancer Chemotherapy Under NCD 291

Covered CPT and HCPCS Codes

NCD 291 does not list specific CPT or HCPCS codes. This is worth flagging — the absence of specific codes means your billing team needs to rely on internal charge master mappings and MAC-specific guidance for the correct drug administration and drug supply codes.

For colorectal cancer chemotherapy billing, the relevant codes typically come from the J-code range for drug supply (such as J-codes for oxaliplatin, irinotecan, cetuximab, and bevacizumab) and CPT codes for chemotherapy infusion administration. But NCD 291 itself does not specify them. Use your MAC's billing guidelines and current HCPCS drug codes to map these agents correctly.

Key ICD-10-CM Diagnosis Codes

NCD 291 does not list specific ICD-10-CM codes. Colorectal cancer diagnosis coding will typically draw from the C18–C20 range (malignant neoplasms of the colon and rectum), but confirm the appropriate codes with your clinical documentation team based on the specific tumor site and stage.

Do not rely on this blog post for specific code assignments. Because NCD 291 contains no code-level guidance, your MAC's local coverage determination and drug-specific J-code references are the definitive source.

The Real Issue With This Policy

Here's the honest read: NCD 291 is a framework policy, not a lookup table. It tells you the rules for coverage — FDA-approved, compendium-supported, or CMS-identified trial. But it doesn't hand you a code list or a prior authorization checklist. That makes it easy to treat as background noise. That's a mistake.

The January 9, 2026 modification keeps the CMS colorectal cancer chemotherapy coverage policy intact while reaffirming that clinical trial coverage applies specifically to the NCI trials on the CMS list. If your facility participates in oncology research, that distinction is financially meaningful. Off-label use in an unlisted trial is not covered under NCD 291 — it falls back to MAC discretion. That's a real reimbursement gap if you're not tracking which trials are on the list.

The policy also explicitly preserves MAC authority for off-label uses outside the identified trials. That means two facilities billing the same off-label use of bevacizumab for the same cancer type could get different coverage outcomes based on which MAC jurisdiction they're in. That kind of variability demands that your billing team knows your MAC's position — not just the NCD.